Literature DB >> 20696831

Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach.

Sukanya Raghavan1, Anna Karin Ostberg, Carl-Fredrik Flach, Annelie Ekman, Margareta Blomquist, Cecil Czerkinsky, Jan Holmgren.   

Abstract

Sublingual (SL) immunization has been described as an effective novel way to induce mucosal immune responses in the respiratory and genital tracts. We examined the potential of SL immunization against Helicobacter pylori to stimulate immune responses in the gastrointestinal mucosa and protect against H. pylori infection. Mice received two SL immunizations with H. pylori lysate antigens and cholera toxin as an adjuvant, and after challenge with live H. pylori bacteria, their immune responses and protection were evaluated, as were immune responses prior to challenge. SL immunization induced enhanced proliferative responses to H. pylori antigens in cervicomandibular lymph nodes and provided at least the same level of immune responses and protection as corresponding intragastric immunization. Protection in SL-immunized mice was associated with strong H. pylori-specific serum IgG and IgA antibody responses in the stomach and intestine, with strong proliferation and gamma interferon (IFN-γ) and interleukin-17 (IL-17) production by spleen and mesenteric lymph node T cells stimulated with H. pylori antigens in vitro, and with increased IFN-γ and IL-17 gene expression in the stomach compared to levels in infected unimmunized mice. Immunohistochemical studies showed enhanced infiltration of CD4(+) T cells and CD19(+) B cells into the H. pylori-infected stomach mucosa of SL-immunized but not unimmunized H. pylori-infected mice, which coincided with increased expression of the mucosal addressin cell adhesion molecule (MAdCAM-1) and T and B cell-attracting chemokines CXCL10 and CCL28. We conclude that, in mice, SL immunization can effectively induce protection against H. pylori infection in association with strong T and B cell infiltration into the stomach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696831      PMCID: PMC2950356          DOI: 10.1128/IAI.00536-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Lymphocyte trafficking and regional immunity.

Authors:  E C Butcher; M Williams; K Youngman; L Rott; M Briskin
Journal:  Adv Immunol       Date:  1999       Impact factor: 3.543

2.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Joo-Hye Song; Catherine Hervouet; Carmelo Luci; Jia-Bin Sun; Paul Hofman; Jan Holmgren; Fabienne Anjuère; Cecil Czerkinsky
Journal:  Vaccine       Date:  2007-10-25       Impact factor: 3.641

3.  Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions.

Authors:  J Pappo; D Torrey; L Castriotta; A Savinainen; Z Kabok; A Ibraghimov
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.

Authors:  Johanna Nyström; S Raghavan; A-M Svennerholm
Journal:  Microbes Infect       Date:  2005-09-22       Impact factor: 2.700

7.  Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa.

Authors:  Konstantinos A Papadakis; John Prehn; Daocheng Zhu; Carol Landers; Joanne Gaiennie; Phillip R Fleshner; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2004-11       Impact factor: 5.325

8.  Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication.

Authors:  Yaron Niv; Rachel Hazazi
Journal:  Helicobacter       Date:  2008-02       Impact factor: 5.753

Review 9.  Progress in vaccine development against Helicobacter pylori.

Authors:  Ann-Mari Svennerholm; Anna Lundgren
Journal:  FEMS Immunol Med Microbiol       Date:  2007-04-18

10.  Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.

Authors:  T H Ermak; P J Giannasca; R Nichols; G A Myers; J Nedrud; R Weltzin; C K Lee; H Kleanthous; T P Monath
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  26 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

2.  Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.

Authors:  Carl-Fredrik Flach; Anna Karin Östberg; Anne-Therese Nilsson; Rene De Waal Malefyt; Sukanya Raghavan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 3.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.

Authors:  Prosper N Boyaka
Journal:  J Immunol       Date:  2017-07-01       Impact factor: 5.422

4.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

5.  Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.

Authors:  Tara L Martin; Junbae Jee; Eunsoo Kim; Haley E Steiner; Estelle Cormet-Boyaka; Prosper N Boyaka
Journal:  Vaccine       Date:  2017-03-24       Impact factor: 3.641

6.  Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Authors:  John G Nedrud; Nayer Bagheri; Karin Schön; Wei Xin; Hilda Bergroth; Dubravka Grdic Eliasson; Nils Y Lycke
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Authors:  William Domm; Lauren Brooks; Hung Li Chung; Changyong Feng; William J Bowers; Gene Watson; James L McGrath; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

8.  A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.

Authors:  Louise Sjökvist Ottsjö; Carl-Fredrik Flach; John Clements; Jan Holmgren; Sukanya Raghavan
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

9.  Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice.

Authors:  Marianne Quiding-Järbrink; Sukanya Raghavan; Malin Sundquist
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

10.  Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization.

Authors:  Louise Sjökvist Ottsjö; Frida Jeverstam; Linda Yrlid; Alexander U Wenzel; Anna K Walduck; Sukanya Raghavan
Journal:  Immunology       Date:  2016-11-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.